Effect of Choline Alfoscerate on the Progression From Mild Cognitive Impairment to Dementia: Distributed Network Analysis of a Multicenter Korean Database Using a Common Data Model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose: Choline alfoscerate (CA) is an acetylcholine precursor known for its beneficial effect on cognition in patient with Alzheimer’s disease dementia (ADD). However, there is little evidence of its effects in patients with mild cognitive impairment (MCI). We assessed the influence of CA on the progression from MCI to all-cause dementia or ADD in three observational Korean databases using a Common Data Model (CDM). Methods: Patients who were diagnosed with MCI and were aged over 60 years were included. After propensity score matching, 3,062 matched pairs patients using CA use and those not using CA were included. The Cox regression model was used to analyze the hazard ratio (HR) of CA use for conversion from MCI to all-cause dementia or ADD. Subgroup analyses were performed based on sex, acetylcholine esterase inhibitor (AchEI) use, and donepezil use. Results: A meta-analysis across three hospitals revealed that CA use was not associated with the progression from MCI to all-cause dementia (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.59–1.26) or ADD (HR, 1.05; 95% CI, 0.51–1.59). Subgroup analyses revealed that CA use was not related to progression to all-cause dementia or ADD when stratified by sex, AchEI use, and donepezil use. Conclusions: In this multicenter cohort study based on the Observational Medical Outcomes Partnership CDM real-world data, no association was noted between CA use and disease progression from MCI to all-cause dementia or ADD.
Abstract
Background and Purpose: Choline alfoscerate (CA) is an acetylcholine precursor known for its beneficial effect on cognition in patient with Alzheimer’s disease dementia (ADD). However, there is little evidence of its effects in patients with mild cognitive impairment (MCI). We assessed the influence of CA on the progression from MCI to all-cause dementia or ADD in three observational Korean databases using a Common Data Model (CDM). Methods: Patients who were diagnosed with MCI and were aged over 60 years were included. After propensity score matching, 3,062 matched pairs patients using CA use and those not using CA were included. The Cox regression model was used to analyze the hazard ratio (HR) of CA use for conversion from MCI to all-cause dementia or ADD. Subgroup analyses were performed based on sex, acetylcholine esterase inhibitor (AchEI) use, and donepezil use. Results: A meta-analysis across three hospitals revealed that CA use was not associated with the progression from MCI to all-cause dementia (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.59–1.26) or ADD (HR, 1.05; 95% CI, 0.51–1.59). Subgroup analyses revealed that CA use was not related to progression to all-cause dementia or ADD when stratified by sex, AchEI use, and donepezil use. Conclusions: In this multicenter cohort study based on the Observational Medical Outcomes Partnership CDM real-world data, no association was noted between CA use and disease progression from MCI to all-cause dementia or ADD.
참고문헌 (23)
- "2023 Alzheimer’s disease facts and figures", Alzheimers Dement, 19, pp.1598~1695 (2023)
- McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.270~279 (2011)
- Francis PT, "The cholinergic hypothesis of Alzheimer’s disease : a review of progress", J Neurol Neurosurg Psychiatry, 66, pp.137~147 (1999)
- Arendt T, "Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer’s disease", Neuroscience, 14, pp.1~14 (1985)
- Davies P, "Selective loss of central cholinergic neurons in Alzheimer’s disease", Lancet, 2, pp.1403~ (1976)
- Reinikainen KJ, "Neurotransmitter changes in Alzheimer’s disease : implications to diagnostics and therapy", J Neurosci Res, 27, pp.576~586 (1990)
- Haense C, "Cholinergic system function and cognition in mild cognitive impairment", Neurobiol Aging, 33, pp.867~877 (2012)
- Sigala S, "L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat", Eur J Pharmacol, 211, pp.351~358 (1992)
- Amenta F, "Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine : an approach for enhancing cholinergic neurotransmission", Mech Ageing Dev, 127, pp.173~179 (2006)
- Amenta F, "The ASCOMALVA trial : association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury : interim results", J Neurol Sci, 322, pp.96~101 (2012)
- Amenta F, "The ASCOMALVA(Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer’s Disease)trial : interim results after two years of treatment", J Alzheimers Dis, 42(Suppl 3), pp.S281~S288 (2014)
- Traini E, "Choline alphoscerate(alpha-glyceryl-phosphoryl-choline)an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent", Curr Alzheimer Res, 10, pp.1070~1079 (2013)
- Hripcsak G, "Observational Health Data Sciences and Informatics(OHDSI) : opportunities for observational researchers", Stud Health Technol Inform, 216, pp.574~578 (2015)
- Voss EA, "Feasibility and utility of applications of the common data model to multiple, disparate observational health databases", J Am Med Inform Assoc, 22, pp.553~564 (2015)
- Yoon D, "Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a Common Data Model for distributed network research", Healthc Inform Res, 22, pp.54~58 (2016)
- You SC, "Conversion of National Health Insurance Service-National Sample Cohort(NHIS-NSC)database into Observational Medical Outcomes Partnership-Common Data Model(OMOP-CDM)", Stud Health Technol Inform, 245, pp.467~470 (2017)
- Han SH, "Quantitative electroencephalography changes in patients with mild cognitive impairment after choline alphoscerate administration", J Clin Neurosci, 102, pp.42~48 (2022)
- Kwak YT, "Quantitative EEG findings in different stages of Alzheimer’s disease", J Clin Neurophysiol, 23, pp.456~461 (2006)
- Jelic V, "Quantitative electroencephalography power and coherence in Alzheimer’s disease and mild cognitive impairment", Dementia, 7, pp.314~323 (1996)
- Han SH, "P300 latency changes in patients with mild cognitive impairment after taking choline alphoscerate; a preliminary study", eNeurologicalSci, 11, pp.5~8 (2018)
- Beam CR, "Differences between women and men in incidence rates of dementia and Alzheimer’s disease", J Alzheimers Dis, 64, pp.1077~1083 (2018)
- Sagaro GG, "Activity of choline alphoscerate on adult-onset cognitive dysfunctions : a systematic review and meta-analysis", J Alzheimers Dis, 92, pp.59~70 (2023)